The New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE study evaluating erenumab versus placebo for the prevention of episodic migraine. Erenumab is a treatment specifically designed to prevent migraine by blocking the CGRP receptor, which is associated with migraine activation. It is the first and only fully human monoclonal antibody designed to specifically block the calcitonin gene-related peptide (CGRP) receptor; CGRP plays a critical role in migraine activation. The active substance has been studied on more than 2600 patients in several large global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention. Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study. Patients taking erenumab experienced a significant reduction in mean monthly migraine days and were significantly more likely to achieve a 50% or greater reduction in monthly migraine days than those taking placebo. STRIVE is a Phase III, global, multicenter, randomized 24-week, double-blind, placebo-controlled. In the study, 955 patients were randomized to receive once-monthly subcutaneous placebo, or erenumab (70 mg or 140 mg) in a 1:1:1 ratio. Patients experienced between four and 14 migraine days each month, with an average of 8.3 migraine days per month at baseline. The primary endpoint was change in mean monthly migraine days from baseline over the last three months of the double-blind treatment phase of the study (months 4, 5 and 6). Secondary study endpoints assessed at six months included reduction of at least 50 percent from baseline in mean monthly migraine days, change from baseline in mean monthly acute migraine-specific medication days, and reductions from baseline in both mean impact on everyday activities domain and mean physical impairment domain scores on the Migraine Physical Function Impact Diary (MPFID).